Role Definition
| Field | Value |
|---|---|
| Job Title | Pharmacogenomics Specialist |
| Seniority Level | Mid-Level (3-7 years post-qualification) |
| Primary Function | Interprets pharmacogenomic test results (CYP2D6, CYP2C19, CYP2C9/VKORC1, DPYD, TPMT, etc.), advises clinicians on drug-gene interactions using CPIC and DPWG guidelines, develops PGx-informed prescribing protocols integrated into EHR clinical decision support, counsels patients on PGx implications for their medications, and contributes to institutional PGx programme development. Works across oncology, psychiatry, cardiology, pain management, and anticoagulation services. |
| What This Role Is NOT | NOT a clinical pharmacist doing general ward-based medication review (broader scope, less genomics focus). NOT a genetic counselor (broader inherited disease risk, not drug-response focused). NOT a bioinformatician (computational pipeline development, not clinical interpretation). NOT a laboratory geneticist (bench sequencing and variant calling, not prescribing advice). |
| Typical Experience | 3-7 years. PharmD or MSc in pharmacogenomics/clinical pharmacology. UK: GPhC registration + postgraduate PGx training, often within NHS Genomic Medicine Service. US: state licensure + PGY1/PGY2 residency with PGx focus, or PhD in pharmacogenomics with clinical appointment. Board certification (BCPS with PGx focus) or equivalent. |
Seniority note: A junior pharmacist with basic PGx awareness but no specialist training would score lower Yellow (~35-38). A senior PGx programme director leading institutional implementation, conducting research, and publishing CPIC guideline updates would score higher (low Green, ~50-54) due to strategic complexity and research depth.
Protective Principles + AI Growth Correlation
| Principle | Score (0-3) | Rationale |
|---|---|---|
| Embodied Physicality | 0 | Fully desk/screen-based. PGx consultation is cognitive — reviewing genotype results, cross-referencing guidelines, advising clinicians. No physical examination or hands-on component. Teleconsultation is routine. |
| Deep Interpersonal Connection | 2 | Patient counselling on PGx results requires empathy and communication skill — explaining why a medication is being changed based on genetics, addressing anxiety about genetic testing, and supporting shared decision-making. Clinician consultation requires trust and persuasion to change established prescribing habits. |
| Goal-Setting & Moral Judgment | 2 | Independently interprets ambiguous genotype-phenotype correlations, recommends dosing adjustments in complex polypharmacy, decides when to override standard CPIC recommendations based on patient-specific factors, and exercises professional judgment on clinical significance of novel variants. |
| Protective Total | 4/9 | |
| AI Growth Correlation | 0 | Demand driven by expanding PGx testing adoption, precision medicine initiatives (NHS Genomic Medicine Service, US All of Us), and growing drug-gene evidence base — not by AI adoption itself. AI tools augment the role but do not create additional demand for human PGx specialists. Neutral. |
Quick screen result: Protective 4/9 with neutral correlation = Likely Yellow. The zero physicality and high data-interpretation component suggest meaningful AI exposure. Proceed to quantify.
Task Decomposition (Agentic AI Scoring)
| Task | Time % | Score (1-5) | Weighted | Aug/Disp | Rationale |
|---|---|---|---|---|---|
| PGx test result interpretation and drug-gene interaction analysis | 25% | 3 | 0.75 | AUGMENTATION | Core analytical task: matching genotype to phenotype using CPIC/DPWG guidelines, PharmGKB, and clinical evidence. AI tools (Sherpa Rx, GeneSight CDS, PGx-Passport) now automate standard genotype-to-phenotype translation and generate initial recommendations with high accuracy. Specialist validates complex cases — star allele combinations, novel variants, phenoconversion from DDIs. AI handles 60-70% of routine lookups; human judgment critical for the ambiguous 30-40%. |
| Clinician consultation and prescribing advice | 20% | 2 | 0.40 | AUGMENTATION | Advising physicians, psychiatrists, and oncologists on PGx-informed prescribing. Requires translating genomic data into actionable clinical recommendations in context of comorbidities, polypharmacy, and patient preferences. Real-time consultation during ward rounds or MDT meetings. AI generates draft recommendations; specialist provides clinical nuance and persuades clinicians to act. |
| CDS development and EHR integration | 15% | 4 | 0.60 | DISPLACEMENT | Building and maintaining PGx clinical decision support alerts within Epic, Cerner, or EMIS. Mapping CPIC guidelines to EHR alert logic. This is increasingly templated — AI generates alert rules from published guidelines, and commercial CDS platforms (First Databank, Wolters Kluwer) embed PGx directly. Specialist configures and validates, but the design and maintenance work is compressing. |
| Patient counselling on PGx results | 15% | 2 | 0.30 | AUGMENTATION | Explaining pharmacogenomic test results to patients — what their CYP2D6 poor metaboliser status means for their antidepressant, why warfarin dosing needs adjustment. Addressing anxiety, cultural concerns, genetic privacy fears. Human connection IS the intervention. AI can generate educational materials; the counselling conversation requires empathy and adaptive communication. |
| PGx programme development and protocol writing | 10% | 3 | 0.30 | AUGMENTATION | Developing institutional PGx implementation plans, writing prescribing protocols, creating formulary recommendations based on PGx evidence. AI drafts protocols from CPIC guidelines and synthesises evidence; specialist adapts to institutional context, secures stakeholder buy-in, and navigates governance. |
| Education and training of clinical staff | 5% | 1 | 0.05 | NOT INVOLVED | Teaching prescribers, pharmacists, and nurses about PGx principles. Running case-based educational sessions. Human teaching in clinical environments. |
| Research, literature review, and guideline monitoring | 5% | 4 | 0.20 | DISPLACEMENT | Tracking new CPIC guideline updates, FDA pharmacogenomic biomarker changes, and emerging drug-gene evidence. AI literature synthesis tools handle systematic scanning of PubMed, PharmGKB updates, and FDA label changes with high accuracy. Specialist reviews but does not need to manually search. |
| Documentation, audit, and quality improvement | 5% | 4 | 0.20 | DISPLACEMENT | Clinical documentation, intervention tracking, PGx utilisation audits, outcome reporting. Structured, rule-based tasks that AI handles effectively. |
| Total | 100% | 2.80 |
Task Resistance Score: 6.00 - 2.80 = 3.20/5.0
Displacement/Augmentation split: 25% displacement, 55% augmentation, 20% not involved.
Reinstatement check (Acemoglu): Partial. AI creates some new tasks — validating AI-generated PGx CDS alerts, interpreting multi-omics integration outputs, overseeing AI-driven phenoconversion detection. But these new tasks are fewer than in broader clinical pharmacy roles because the PGx knowledge domain is narrower and more codifiable. The reinstatement effect is moderate, not strong. Adjusted Task Resistance: 3.25/5.0 (+0.05 for moderate reinstatement).
Evidence Score
| Dimension | Score (-2 to 2) | Evidence |
|---|---|---|
| Job Posting Trends | 1 | Growing but from a very small base. PGx specialist postings appearing on NHS Jobs (NHS Genomic Medicine Service expansion), Indeed, and academic medical centres. BLS does not track PGx specialists separately. Indeed (2025) lists careers in pharmacogenomics as emerging. NHS Genomic Medicine Service creating new PGx roles in regional genomic hubs (Cambridge, Oxford, London). US: academic health systems and commercial PGx labs (Myriad, OneOme, Tempus) hiring. Positive trajectory, small absolute numbers. |
| Company Actions | 0 | Mixed. PGx testing companies expanding (Tempus, OneOme), but many health systems absorb PGx work into existing clinical pharmacist roles rather than creating dedicated specialist posts. No systemic cuts citing AI, but no major dedicated PGx hiring waves either. Neutral. |
| Wage Trends | 1 | UK: NHS Band 7-8a (£43,742-£57,349) for specialist pharmacist roles; private sector PGx roles £60,000-£90,000. US: $80,000-$160,000 depending on setting (academic vs industry, geographic location). Boston/SF biotech hubs command premiums. Competitive within pharmacy, with AI/genomics proficiency adding 10-15% premium. |
| AI Tool Maturity | 0 | Sherpa Rx (2025) outperforms ChatGPT on 260 PGx queries. GeneSight, PGx-Passport, and commercial CDS platforms embed CPIC guidelines directly. AI automates routine genotype-to-phenotype translation with high accuracy. But complex cases (novel variants, phenoconversion, multi-gene polypharmacy interactions) still require specialist judgment. Production-grade augmentation; not yet displacing the specialist for complex work. Neutral — strong augmentation. |
| Expert Consensus | 1 | ScienceDirect (Jun 2025): "Pharmacogenomics entering transformative phase with AI integration." American PGx Association (Dec 2025): Sherpa Rx shows AI can deliver actionable PGx guidance. CPIC continues publishing guidelines assuming human clinical oversight. Consensus: AI augments PGx interpretation, specialist role shifts to complex validation and clinical integration. |
| Total | 3 |
Barrier Assessment
Reframed question: What prevents AI execution even when programmatically possible?
| Barrier | Score (0-2) | Rationale |
|---|---|---|
| Regulatory/Licensing | 2 | PharmD/GPhC registration or equivalent clinical qualification required. Prescribing recommendations require licensed professional sign-off. No regulatory pathway for AI to independently advise on prescribing changes based on genomic data. MHRA and FDA require human clinical oversight for PGx-guided treatment decisions. |
| Physical Presence | 0 | Fully deliverable remotely. PGx consultation is screen-based — reviewing genotype reports, consulting EHR data, advising clinicians via phone/video. Teleconsultation is standard practice. No physical barrier whatsoever. |
| Union/Collective Bargaining | 0 | No meaningful union representation specific to PGx specialists. At-will employment predominates in both US and UK settings. |
| Liability/Accountability | 2 | PGx specialist bears professional liability for prescribing recommendations. Incorrect genotype-phenotype interpretation can lead to adverse drug reactions, treatment failure, or fatal toxicity (e.g., DPYD deficiency and fluorouracil). A human must bear accountability for clinical decisions based on genomic data. |
| Cultural/Ethical | 2 | Patients and clinicians expect a qualified human specialist to interpret genomic data affecting their medication. Genetic privacy concerns amplify the expectation of human oversight. Cultural resistance to AI making medication-changing decisions based on DNA data is significant — genetic exceptionalism applies here. Clinicians also require persuasion from a trusted human colleague to change established prescribing habits based on PGx results. |
| Total | 6/10 |
AI Growth Correlation Check
Confirmed at 0 (Neutral). PGx specialist demand is driven by expanding pharmacogenomic testing adoption, decreasing test costs, growing CPIC guideline coverage (now 25+ gene-drug pairs), precision medicine policy initiatives (NHS Genomic Medicine Service, US All of Us Programme), and the ageing population's increasing polypharmacy complexity. AI tools accelerate PGx adoption by making test interpretation more accessible, which could indirectly increase demand for specialists to handle complex cases — but this is a secondary effect, not a direct AI-creates-demand dynamic. Not Accelerated Green.
JobZone Composite Score (AIJRI)
| Input | Value |
|---|---|
| Task Resistance Score | 3.25/5.0 |
| Evidence Modifier | 1.0 + (3 x 0.04) = 1.12 |
| Barrier Modifier | 1.0 + (6 x 0.02) = 1.12 |
| Growth Modifier | 1.0 + (0 x 0.05) = 1.00 |
Raw: 3.25 x 1.12 x 1.12 x 1.00 = 4.0768
JobZone Score: (4.0768 - 0.54) / 7.93 x 100 = 44.6/100
Zone: YELLOW (Green >=48, Yellow 25-47, Red <25)
Sub-Label Determination
| Metric | Value |
|---|---|
| % of task time scoring 3+ | 60% |
| AI Growth Correlation | 0 |
| Sub-label | Yellow (Urgent) — AIJRI 25-47 AND >=40% of task time scores 3+ |
Assessor override: Score accepted at 44.6. Three calibration peers confirm positioning: Clinical Pharmacist Ward-Based (54.4, Green Transforming) and Medicines Optimisation Pharmacist (54.9, Green Transforming) score ~10 points higher because they have broader clinical scope, more patient contact time at score 1-2, and physical presence on wards. Genetic Counselor (45.2, Yellow Urgent) is the closest peer — both are specialist interpretation roles with high analytical AI exposure but protected psychosocial counselling components. The PGx specialist scores 0.6 points below the Genetic Counselor, which is correct: the PGx specialist's knowledge domain is more codifiable (CPIC guidelines are machine-readable), the CDS development work is more automatable, and the patient counselling component is smaller (15% vs 30%).
Assessor Commentary
Score vs Reality Check
The 44.6 Yellow (Urgent) score places this role 3.4 points below the Green boundary. The score accurately reflects a specialist whose analytical core — CPIC guideline application, genotype-phenotype translation, CDS alert logic — is highly codifiable and already being automated by production tools (Sherpa Rx, GeneSight, PGx-Passport). The 60% of task time scoring 3+ is among the highest in the pharmacy specialism cluster, driven by the fact that pharmacogenomics is fundamentally a knowledge-retrieval-and-application discipline — precisely where AI excels. The barrier score (6/10) provides meaningful protection through licensing and liability, but the zero physicality and zero union protection leave structural gaps that broader clinical pharmacy roles fill.
What the Numbers Don't Capture
- The codifiability gap matters here more than in general pharmacy. CPIC guidelines are published in machine-readable formats. PharmGKB is a structured database. The core PGx knowledge base is systematically organised for computational consumption in a way that general clinical pharmacy knowledge is not. This makes the analytical tasks more AI-accessible than the score alone suggests.
- Institutional absorption risk. Many health systems are integrating PGx interpretation into existing clinical pharmacist and genetic counselor roles rather than creating dedicated PGx specialist posts. AI CDS tools accelerate this by making PGx interpretation accessible to generalists. The dedicated specialist role may contract even as PGx testing expands.
- NHS Genomic Medicine Service is a structural tailwind. In the UK specifically, the government's commitment to embedding genomics in routine care creates protected demand for PGx expertise. But whether this demand is met by dedicated specialists or upskilled clinical pharmacists is an open question.
Who Should Worry (and Who Shouldn't)
PGx specialists who focus on complex clinical consultation — advising oncologists on DPYD testing before fluoropyrimidines, managing psychiatric polypharmacy with CYP2D6/CYP2C19 interactions, counselling patients through medication changes — are the safest. The judgment, persuasion, and patient interaction components resist automation.
PGx specialists whose primary output is CDS configuration, guideline translation into EHR alert logic, or routine genotype-to-phenotype reporting should pay close attention. This is the work AI already does well, and commercial platforms are embedding it directly into EHR workflows without a dedicated specialist in the loop.
The single biggest factor: whether your daily work centres on patient-facing counselling and complex clinical judgment (protected) or guideline-to-CDS translation and routine interpretation (transforming).
What This Means
The role in 2028: PGx specialists will use AI for automated genotype-phenotype translation, CDS alert generation, literature surveillance, and draft protocol writing. The specialist becomes the clinical validator for complex cases — phenoconversion in polypharmacy, novel variants not yet in CPIC, multi-omics integration — and the trusted advisor who persuades clinicians to act on PGx data. Routine PGx interpretation increasingly handled by AI-augmented generalist pharmacists.
Survival strategy:
- Build deep clinical subspecialty expertise in high-complexity areas — oncology PGx (DPYD, UGT1A1), psychiatric PGx (multi-gene interactions with polypharmacy), and transplant immunosuppression — where ambiguity and stakes are highest
- Become the AI oversight expert — the specialist who validates AI-generated PGx CDS, configures institution-specific alert parameters, and trains generalist pharmacists to use PGx tools correctly
- Maximise patient-facing time — counsel patients, attend MDT meetings, and present at tumour boards rather than spending time on guideline lookups and CDS maintenance that AI handles better
Where to look next. If you are considering a career shift, these Green Zone roles share transferable skills with pharmacogenomics:
- Clinical Pharmacist Ward-Based (Mid-Level) (AIJRI 54.4) — broader clinical scope with more patient contact; PGx knowledge becomes a differentiating subspecialty within a more protected role
- Medicines Optimisation Pharmacist (Mid-Senior) (AIJRI 54.9) — polypharmacy management and deprescribing leverage PGx knowledge; more patient-facing, more structurally protected
- Genetic Counselor (Mid-Level) (AIJRI 45.2) — shares the genomic interpretation skillset; stronger psychosocial counselling component provides additional protection
Browse all scored roles at jobzonerisk.com to find the right fit for your skills and interests.
Timeline: 3-5 years. Driven by the pace of AI PGx CDS maturity (already production-grade for routine cases), institutional decisions about dedicated vs integrated PGx roles, and the small workforce size that amplifies any structural shift.
